SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.

30 August 2025 (13:15 - 14:00)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Luigi Spadafora

Sapienza University of Rome, Latina (Italy)

3 More presentations in this session

Presentation thumbnail

Right vs. left cardiac function and structure: impact of SGLT2i in acute decompensate heart failure with central sleep apnea

Assistant Professor P. Kalaydzhiev (Sofia, BG)

Abstract Slides Video

Presentation thumbnail

Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation

Associate Professor V. Vintila (Bucharest, RO)

Abstract Slides Video

Presentation thumbnail

THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure.

Doctor S. Das (Boston, US)

Access the full session

Session thumbnail

SGLT2 inhibitors in heart failure: prevention and treatment

The Event

Event poster

ESC Congress 2025

30 August 2025 13:15 CET

You may be interested in

Congress Presentation

The cardioprotective effect of inhibitor sodium glucose transporter in patients undergoing chemotherapy: a systematic review and meta-analysis

Congress Presentation

Cardiovascular outcomes of sodium glucose co-transporter-2 inhibitor treatment in cancer patients receiving anthracycline chemotherapy: a systematic review and meta-analysis

Congress Presentation

SGLT2 inhibitors and cardiotoxicity in diabetic patients receiving anthracycline therapy: a retrospective study

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources